Holen Sie sich die Stockscreener-App
12.44
6.60%
0.77
Handel nachbörslich:
12.44
Schlusskurs vom Vortag:
$11.67
Offen:
$11.56
24-Stunden-Volumen:
47,754
Relative Volume:
2.10
Marktkapitalisierung:
$29.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.85M
KGV:
-40.13
EPS:
-0.31
Netto-Cashflow:
$-3.95M
1W Leistung:
+20.19%
1M Leistung:
-8.12%
6M Leistung:
-19.74%
1J Leistung:
+71.00%
1-Tages-Spanne:
$11.21
$12.68
1-Wochen-Bereich:
$10.02
$13.71
52-Wochen-Spanne:
$5.70
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Firmenname
Cadrenal Therapeutics Inc
Sektor
Branche
Telefon
904-300-0701
Adresse
822 A1A NORTH, PONTE VEDRA
Vergleichen Sie CVKD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
12.44 | 29.50M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-18 | Eingeleitet | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Down 0.1% – Here’s What Happened - Defense World
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients - BioSpace
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - BioSpace
(CVKD) Technical Pivots with Risk Controls - news.stocktradersdaily.com
What is Zacks Small Cap’s Estimate for CVKD FY2025 Earnings? - Defense World
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin… - MSN
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin - research-tree.com
Cadrenal Therapeutics (NASDAQ:CVKD) Earns Buy Rating from HC Wainwright - Defense World
(CVKD) Proactive Strategies - news.stocktradersdaily.com
Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone - TipRanks
Cadrenal Therapeutics (CVKD) Receives Buy Rating from HC Wainwright & Co. | CVKD Stock News - GuruFocus
Cadrenal Therapeutics advances in tecarfarin production By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics advances in tecarfarin production - Investing.com
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - Business Wire
Cadrenal Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 forNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 - openPR.com
Shares Of This EV Stock Soar On Year-Over-Year Guidance - The Globe and Mail
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) - The Globe and Mail
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) | FinancialContent - FinancialContent
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD | FinancialContent - FinancialContent
Cisco Expands Partnership with Saudi Arabia to Power the AI Future - The Globe and Mail
PRN_FinancialWrapper - FinancialContent
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
CADRENAL THERAPEUTICS Earnings Preview: Recent $CVKD Insider Trading, Hedge Fund Activity, and More - Nasdaq
10,554 Shares in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Purchased by Geode Capital Management LLC - Defense World
Cadrenal Therapeutics (CVKD) to Release Quarterly Earnings on Thursday - Defense World
Sprott Asset Management buying more Sprott Phys. Copper Trust (COP) - The Globe and Mail
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.8% – Here’s Why - Defense World
Trading (CVKD) With Integrated Risk Controls - news.stocktradersdaily.com
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq - BioSpace
Cadrenal Therapeutics Reveals Latest Phase 3 Anticoagulant Progress at Exclusive Nasdaq Conference - Stock Titan
Cadrenal Therapeutics IncFiles Prospectus Supplement For $2.17 Million ATM Offering - marketscreener.com
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans? - Yahoo
When (CVKD) Moves Investors should Listen - news.stocktradersdaily.com
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - BioSpace
Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan
Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World
(CVKD) Trading Advice - Stock Traders Daily
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News
Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks
Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView
Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace
Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com
Finanzdaten der Cadrenal Therapeutics Inc-Aktie (CVKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):